$1.1 trillion. 36 countries. One drug class.
A new fiscal model of GLP-1 drugs across 55 countries identifies approximately $1.1 trillion in cumulative net fiscal returns governments could capture by 2050. The biggest opportunity sits in 19 of 21 high-income countries that should launch national programmes now — before generic semaglutide arrives in 2032. Most won’t. Third and final post in the GLP-1 trilogy. Link in image
